Atwood & Palmer Inc. Trims Stake in Danaher Corporation $DHR

Atwood & Palmer Inc. reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 17.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,145 shares of the conglomerate’s stock after selling 235 shares during the period. Atwood & Palmer Inc.’s holdings in Danaher were worth $226,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. boosted its position in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at $27,000. Sierra Ocean LLC lifted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the first quarter valued at $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 67 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 11.20% of the company’s stock.

Danaher Trading Down 2.6%

Shares of DHR opened at $190.07 on Monday. The firm’s fifty day moving average is $201.21 and its two-hundred day moving average is $198.78. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market cap of $136.10 billion, a PE ratio of 40.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is presently 27.23%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research reports. Guggenheim reissued a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Wells Fargo & Company lowered their target price on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Evercore ISI reduced their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. UBS Group cut their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Finally, Robert W. Baird lifted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.